Natalie Receives F31 Fellowship Award

June 30, 2022

Natalie received an NIH F31 Fellowship Award to continue to fund her outstanding work in developing T cell based-cancer immunotherapies. Congratulations Natalie!

Panam Becomes Dr. Chaisawangwong

May 23, 2022

Congratulations Panam!

Gary Wang, MSc

May 19, 2022

Congratulations Gary!

Ariel Becomes Dr. Isser

May 10, 2022

Congratulations Ariel!

Ariel Isser Receives Siebel Scholar Program Award

September 22, 2021

Ariel was selected as a 2022 Siebel Scholar – joining a rare cohort selected for their exceptional academic performance and outstanding leadership. Congratulations Ariel!

NexImmune Announces Closing of Upsized Initial Public Offering

NexImmune Expands Executive Team With Appointments of Chief Medical Officer and Chief Financial Officer - BioHealth Capital Region

February 17, 2021

NexImmune, a clinical stage biotechnology company, closes it’s initial public offering for over $125 million in gross proceeds before costs. Dr. Jonathan Schneck is the Scientific Founder and a member of the Scientific Advisory Board at NexImmune, who’s roots began from technology initially developed from nanoparticle based artificial antigen presenting cells in the Schneck lab.

John Hickey received the Siebel Scholar Program Award

Scientists Advance Creation of ‘Artificial Lymph Node’ to Fight Cancer, Other Diseases, 04/18/2019

Class app: John Hickey creates tool that lets teachers know what’s working—and what isn’t

Nano-sized Magnetic Artificial Cells for Cancer Immunotherapy and Diagnosis

Alyssa Kosmides named a 2018 Siebel Scholar

‘Immunoswitch’ particles may be key to more-effective cancer immunotherapy

Nanoparticle doubles-up tumor targeting

Dual Strategy Teaches Mouse Immune Cells to Overcome Cancer’s Evasive Techniques

Combo treatment harnesses immune system to fight skin cancer